TMDX Stock Recent News

ANDOVER, Mass. , Aug. 20, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on August 16, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 3,073 shares of its common stock and an aggregate of 2,003 restricted stock units to 4 employees, each as a material inducement for each employee's entry into employment with TransMedics.

Recently, U.S. stock markets have been more volatile than usual. TransMedics stock has surged thanks to revenue that has more than doubled this year.

TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX crossed above the 20-day moving average, suggesting a short-term bullish trend.

TransMedics Group, Inc. reported 117.9% YoY revenue growth in Q2 2024 and raised full-year guidance significantly, showcasing strong financial performance. Acquisition of Summit Aviation and building the largest transplant logistics network in the US enhances its competitive moat. Conservative guidance, potential for continued revenue and margin expansion, and robust management led by a visionary CEO position, position TransMedics Group for sustained growth.

TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

TransMedics Group had a remarkable second quarter, beating revenue estimates and raising guidance. The company's National Organ Care Systems Program is driving growth, with liver revenues up 2.4x and heart revenues doubling year over year. Long-term valuation model predicts significant EPS growth, with potential for the stock to reach $265 a share by 2026, representing 75% upside.

SVM, IBCP, TMDX, WT and YELP have been added to the Zacks Rank #1 (Strong Buy) List on August 2, 2024.

The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

TransMedics Group reported significant top- and bottom-line improvement in Q2. The company raised its full-year revenue guidance.

Revenue of $114.3 million, a 118% increase year over year. Full-year revenue guidance increased to $425 million to $445 million.